Zynex (NASDAQ:ZYXI) Releases Earnings Results

Zynex (NASDAQ:ZYXI) posted its quarterly earnings results on Thursday. The company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.06 by $0.01, Briefing.com reports. Zynex had a return on equity of 14.15% and a net margin of 3.12%. The business had revenue of $49.97 million for the quarter, compared to analyst estimates of $50.83 million. During the same quarter in the previous year, the firm earned $0.10 EPS. The company’s quarterly revenue was up .1% compared to the same quarter last year.

Zynex Trading Up 4.3 %

ZYXI stock traded up $0.37 during mid-day trading on Friday, hitting $8.96. 133,969 shares of the company were exchanged, compared to its average volume of 173,262. Zynex has a 12-month low of $7.04 and a 12-month high of $13.77. The firm has a market capitalization of $284.39 million, a P/E ratio of 51.72 and a beta of 0.54. The business has a fifty day simple moving average of $7.96 and a 200-day simple moving average of $9.23. The company has a quick ratio of 3.22, a current ratio of 4.06 and a debt-to-equity ratio of 1.79.

Insider Activity

In related news, Director Joshua R. Disbrow bought 7,000 shares of the company’s stock in a transaction that occurred on Monday, July 29th. The stock was purchased at an average price of $8.32 per share, for a total transaction of $58,240.00. Following the acquisition, the director now owns 72,000 shares of the company’s stock, valued at approximately $599,040. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, COO Anna Lucsok sold 8,083 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $8.03, for a total value of $64,906.49. Following the completion of the transaction, the chief operating officer now owns 16,980 shares of the company’s stock, valued at approximately $136,349.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Joshua R. Disbrow bought 7,000 shares of the business’s stock in a transaction that occurred on Monday, July 29th. The shares were acquired at an average cost of $8.32 per share, for a total transaction of $58,240.00. Following the completion of the purchase, the director now owns 72,000 shares in the company, valued at $599,040. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 52.13% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ZYXI. Royal Bank of Canada dropped their price target on shares of Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. HC Wainwright increased their price objective on Zynex from $16.00 to $17.00 and gave the stock a “buy” rating in a research report on Friday.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.